ADIPO
Adipotide
A peptidomimetic in two parts joined together: a nine-residue homing sequence, CKGGRAKDC, and a dimeric KLAKLAK motif that disrupts mitochondrial membranes. The homing sequence is reported to bind prohibitin. It is a targeting construct rather than a receptor agonist, which is a different design from everything else in this category.
No registered human study names Adipotide as an intervention. ClinicalTrials.gov holds no trial of it, so there is no trial evidence to read — a fact about the public record rather than proof the compound does nothing. No FDA-approved product contains Adipotide. No paper naming Adipotide was published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Adipotide; the registry search is fuzzy, so every match is re-checked. None of this says whether Adipotide works or is safe.
FDA status
Research only
Human studies
0
Furthest phase
—
Papers, 10 yr
0
Readership
58
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
No registered human study
0
Registered human studies
None
No FDA-approved product contains it
No study of Adipotide in humans is registered on ClinicalTrials.gov. That is a fact about the public record, not a statement that the compound does nothing — but it does mean there is no trial evidence to read, and anyone telling you otherwise should be asked for the registration number. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
Is anyone studying Adipotide?
No paper naming “Adipotide” in its title or abstract was published between 2017 and 2026, and no registered trial started in that window. That is a fact about the scientific record, not proof the compound does nothing — but it does mean there is no recent literature to read.
Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02 · check the query.
Published research on Adipotide
The 3 papers PubMed ranks most relevant for Adipotide. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys
- A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication
- Comment on "a peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys"
Collected 2026-08-02from PubMed, phrase-matched on “Adipotide” in title and abstract. Run the same search.
About Adipotide
A peptidomimetic in two parts joined together: a nine-residue homing sequence, CKGGRAKDC, and a dimeric KLAKLAK motif that disrupts mitochondrial membranes. The homing sequence is reported to bind prohibitin. It is a targeting construct rather than a receptor agonist, which is a different design from everything else in this category.
- Also known as
- Prohibitin-targeting peptide-1
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.